RCMU
ABBV icon

Rokos Capital Management (UK)’s AbbVie ABBV Stock Holding History

Rokos Capital Management (UK)’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-134,661
Closed -$15.1M – 100
2021
Q2 		$15.1M Buy
+134,661
New +$15.2M 0.3% 44

Other funds holding ABBV

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rokos Capital Management (UK)'s ABBV Position: Q3 2021 in Review

Rokos Capital Management (UK) sold out of AbbVie (ABBV) in Q3 2021, closing a stake of 134,661 shares — an estimated $15.1M sold.

Rokos Capital Management (UK) first reported a position in ABBV in Q2 2021 and held it in 1 quarter. The position peaked at $15.1M in Q2 2021. 2,655 funds tracked by Wall St. Rank hold ABBV as of Q3 2021.

  • Rokos Capital Management (UK) reported no remaining AbbVie position as of Q3 2021 after selling out during the quarter.
  • Rokos Capital Management (UK) sold 134,661 AbbVie shares in Q3 2021, an estimated $15.1M.
  • Rokos Capital Management (UK) first reported a position in AbbVie in Q2 2021 and held it in 1 quarter.
  • Rokos Capital Management (UK)'s AbbVie position peaked at $15.1M in Q2 2021.
  • 2,655 funds tracked by Wall St. Rank held AbbVie as of Q3 2021.

Based on Rokos Capital Management (UK)'s 13F filing for Q3 2021, filed 15 Nov 2021.